{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:54:22Z","timestamp":1789674862450,"version":"4.0.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":502,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.vaccine.2012.02.005","type":"journal-article","created":{"date-parts":[[2012,2,15]],"date-time":"2012-02-15T08:47:30Z","timestamp":1329295650000},"page":"2510-2515","source":"Crossref","is-referenced-by-count":36,"title":["Modelling the long-term persistence of neutralizing antibody in adults after one dose of live attenuated Japanese encephalitis chimeric virus vaccine"],"prefix":"10.1016","volume":"30","author":[{"given":"Kamal","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Coudeville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bailleux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2012.02.005_bib0005","series-title":"Vaccines","article-title":"Japanese encephalitis vaccines","author":"Halstead","year":"2008"},{"key":"10.1016\/j.vaccine.2012.02.005_bib0010","unstructured":"Centers for Disease Control and Prevention. Japanese Encephalitis Vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2010;59(No. RR-1)."},{"issue":"12","key":"10.1016\/j.vaccine.2012.02.005_bib0015","article-title":"Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses","volume":"10","author":"Mackenzie","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2012.02.005_bib0020","series-title":"Emerging Viruses in Human Populations","article-title":"Japanese encephalitis virus: geographic distribution, incidence, and spread of a virus with a propensity to emerge in new areas","author":"Mackenzie","year":"2007"},{"issue":"8","key":"10.1016\/j.vaccine.2012.02.005_bib0025","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/651271","article-title":"Japanese encephalitis: new options for active immunization","volume":"50","author":"Halstead","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2012.02.005_bib0030","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1586\/erv.11.7","article-title":"New Japanese encephalitis vaccines: alternatives to production in mouse brain","volume":"10","author":"Halstead","year":"2011","journal-title":"Exp Rev Vaccines"},{"issue":"4","key":"10.1016\/j.vaccine.2012.02.005_bib0035","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1128\/JVI.73.4.3095-3101.1999","article-title":"Yellow fever\/Japanese encephalitis chimeric viruses: construction and biological properties","volume":"73","author":"Chambers","year":"1999","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2012.02.005_bib0040","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1006\/viro.1999.9695","article-title":"Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis","volume":"257","author":"Guirakhoo","year":"1999","journal-title":"Virology"},{"issue":"45","key":"10.1016\/j.vaccine.2012.02.005_bib0045","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1016\/j.vaccine.2005.07.002","article-title":"Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2\u20133 September 2004","volume":"23","author":"Hombach","year":"2005","journal-title":"Vaccine"},{"issue":"35","key":"10.1016\/j.vaccine.2012.02.005_bib0050","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1016\/j.vaccine.2011.06.062","article-title":"Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO\u00ae) induced neutralizing antibody titers","volume":"29","author":"Van Gessel","year":"2011","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2012.02.005_bib0055","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.4161\/hv.6.12.13057","article-title":"Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine randomized, double-blind, 5-year phase II study in healthy adults","volume":"6","author":"Nasveld","year":"2010","journal-title":"Hum Vaccines"},{"issue":"8","key":"10.1016\/j.vaccine.2012.02.005_bib0060","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1086\/378356","article-title":"Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen","volume":"188","author":"Monath","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2012.02.005_bib0065","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1002\/sim.3680","article-title":"The BUGS project: evolution, critique and future directions (with discussion)","volume":"28","author":"Lunn","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2012.02.005_bib0070","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","article-title":"Alternative methods for monitoring convergence of iterative simulations","volume":"7","author":"Brooks","year":"1998","journal-title":"J Comput Graph Stat"},{"issue":"4","key":"10.1016\/j.vaccine.2012.02.005_bib0075","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/1467-9868.00353","article-title":"Bayesian measures of model complexity and fit (with discussion)","volume":"64","author":"Spiegelhalter","year":"2002","journal-title":"J Roy Stat Soc Ser B"},{"key":"10.1016\/j.vaccine.2012.02.005_bib0080","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0264-410X(99)00539-3","article-title":"Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster","volume":"18","author":"Tiru","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.02.005_bib0085","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.vaccine.2004.06.012","article-title":"Antidiphtheria antibody seroprotection rates are similar 10 years after vaccination with dTpa or DTPa using a mathematical model","volume":"23","author":"Cheuvart","year":"2004","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2012.02.005_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1096-9071(200001)60:1<1::AID-JMV1>3.0.CO;2-H","article-title":"Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines","volume":"60","author":"Van Herck","year":"2000","journal-title":"J Med Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2012.02.005_bib0095","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/sim.699","article-title":"Repeated-measures models to evaluate a hepatitis B vaccination programme","volume":"20","author":"Renard","year":"2001","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2012.02.005_bib0100","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0264-410X(96)00138-7","article-title":"Persistence of antibodies to meningococcal IgA1 protease versus decay of antibodies to group A polysaccharide and Opc protein","volume":"15","author":"Thiesen","year":"1997","journal-title":"Vaccine"},{"issue":"31","key":"10.1016\/j.vaccine.2012.02.005_bib0105","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1016\/j.vaccine.2008.04.089","article-title":"Predicted long-term persistence of pertussis antibodies in adolescents after an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine, based on mathematical modeling and 5-year observed data","volume":"26","author":"Bailleux","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.02.005_bib0110","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1016\/j.vaccine.2007.02.069","article-title":"Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine","volume":"25","author":"Fraser","year":"2007","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12001697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12001697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T15:50:47Z","timestamp":1713541847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12001697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":22,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0264410X12001697"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.02.005","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}